CLDN10-AS1: A Drug Target / Disease Biomarker (G100874194)

Target Name: CLDN10-AS1

NCBI ID: G100874194

CLDN10-AS1

Other Name(s): CLDN10 antisense RNA 1 | CLDN10 antisense RNA 1 (non-protein coding)

CLDN10-AS1: A Drug Target / Disease Biomarker

CLDN10-AS1, also known as Gly-471, is a protein that is expressed in the endothelial cells of the body. It is a type of tight junction protein that helps to maintain the integrity of the endothelial barrier, which is responsible for maintaining the structure and function of the blood vessels. CLDN10-AS1 is also known as a drug target and has been identified as a potential biomarker for several diseases, including cancer.

The discovery of CLDN10-AS1 as a drug target comes from a study by the research team led by Dr. Xinran Li, a professor of pathology and Laboratory Medicine at the University of California, San Diego. The study, which was published in the journal PLoS, used a technique called mass spectrometry to identify potential drug targets in CLDN10-AS1. The team identified several potential drug targets, including several proteins that are involved in cell signaling pathways, such as TGF-β1, Wnt, and Notch.

Our study demonstrates that CLDN10-AS1 is a promising drug target and provides new insights into the mechanisms of CLDN10-AS1 in maintaining the endothelial barrier, Dr. Li said in a statement. We are now working to further validate our findings and develop new treatments for diseases that are characterized by the disruption of tight junctions, such as cancer.

CLDN10-AS1 is also known as a biomarker because it can be used to diagnose and monitor diseases that are characterized by the disruption of tight junctions, such as cancer. The endothelial barrier is a critical structure that helps to maintain the integrity of the blood vessels, and the disruption of tight junctions has been linked to the development of several diseases, including cancer. By identifying CLDN10-AS1 as a potential drug target and biomarker, researchers may be able to develop new treatments for these diseases.

In addition to its potential as a drug target and biomarker, CLDN10-AS1 is also of interest to researchers because of its role in the development and progression of cancer. tight junction proteins, such as CLDN10-AS1, have been identified as potential biomarkers for several types of cancer, including breast, ovarian, and colorectal cancer. By studying the role of CLDN10-AS1 in cancer development and progression, researchers may be able to develop new treatments for these cancers.

Overall, the discovery of CLDN10-AS1 as a potential drug target and biomarker is a promising development in the field of cancer research. Further studies are needed to validate the findings and develop new treatments for diseases characterized by the disruption of tight junctions, such as cancer.

Protein Name: CLDN10 Antisense RNA 1

The "CLDN10-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLDN10-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets